Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?
Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed.